Institute of Marine Biology, Biotechnology & Aquaculture, Hellenic Centre for Marine Research, 71500 Heraklion, Greece.
Laboratory of Molecular Biology, Department of Biotechnology, School of Food, Biotechnology and Development, Agricultural University of Athens, 11855 Athens, Greece.
Int J Mol Sci. 2023 May 3;24(9):8200. doi: 10.3390/ijms24098200.
, a significant opportunistic marine pathogen, has been a challenge to the aquaculture industry, leading to severe economical and production losses. Phage therapy has been an auspicious approach in controlling such bacterial infections in the era of antimicrobial resistance. In this study, we isolated and fully characterized a novel strain-specific phage, vB_VhaS_MAG7, which infects MM46, and tested its efficacy as a therapeutic agent in challenged gilthead seabream larvae. vB_VhaS_MAG7 is a tailed bacteriophage with a double-stranded DNA of 49,315 bp. No genes linked with virulence or antibiotic resistance were harbored in the genome. The phage had a remarkably large burst size of 1393 PFU cell and showed strong lytic ability in in vitro assays. When applied in phage therapy trials in challenged gilthead seabream larvae, vB_VhaS_MAG7 was capable of improving the survival of the larvae up to 20%. Due to its distinct features and safety, vB_VhaS_MAG7 is considered a suitable candidate for applied phage therapy.
，一种重要的海洋机会致病菌，一直是水产养殖业的挑战，导致严重的经济和生产损失。噬菌体治疗在抗微生物药物耐药性时代控制这种细菌感染是一种有希望的方法。在这项研究中，我们分离并充分表征了一种新型的菌株特异性噬菌体 vB_VhaS_MAG7，它感染 MM46，并测试了它作为治疗剂在 challenged 金头鲷幼鱼中的功效。vB_VhaS_MAG7 是一种有尾噬菌体，双链 DNA 为 49315bp。基因组中没有与毒力或抗生素耐药性相关的基因。噬菌体的爆发量非常大，达到 1393PFU 细胞，在体外试验中表现出很强的裂解能力。当在 challenged 金头鲷幼鱼的噬菌体治疗试验中应用时，vB_VhaS_MAG7 能够将幼鱼的存活率提高到 20%。由于其独特的特征和安全性，vB_VhaS_MAG7 被认为是一种适合应用噬菌体治疗的候选者。
